+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Prostate Cancer Research Program Clinical Consortium Award

Congressionally Directed Medical Research Programs

Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease.

Distinctive Features:

• This award mechanism does not support the development of clinical protocols.

• Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site.

• Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures.

Funding Details:

The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $10.5 million (M) to fund approximately 1 Clinical Consortium Award – Coordinating Center application with a total cost cap of $10.5M. The maximum period of performance is 4 years. The CDMRP expects to allot approximately $22.0M to fund approximately 11 Clinical Consortium – Clinical Research Site applications with total cost caps of $2.0M. The maximum period of performance is 4 years. It is anticipated that awards made from this FY25 funding opportunity will be funded with FY25 funds, which will expire for use on September 30, 2031. Awards supported with FY25 funds will be made no later than September 30, 2026.

AI Based Application Success Predictor

🎯 1. High-Risk, High-Gain & Patient‑Relevant Science

CDMRP intentionally funds innovative, paradigm‑shifting research across the full pipeline—from basic discovery to clinical trials—that addresses critical gaps in health outcomes for service members and the public .

🤝 2. Strong Interdisciplinary & Multi-Investigator Teams

Team‑science mechanisms (e.g., Synergistic Idea Awards) require multiple PIs—each funded independently—not sub-awards, encouraging true synergy across disciplines and institutions .

🔁 3. Two‑Tier Review Incorporating Consumer Input

Tier 1: Peer review assesses technical merit.

Tier 2: Programmatic review weighs scientific excellence alongside program relevance, portfolio balance, and consumer advocate perspectives—consumers have equal voting power  .

🌱 4. Career Development Support for Emerging Researchers

CDMRP includes nested awards for predoctoral, postdoctoral, and clinician-scientist candidates, with programs like the Ovarian Cancer Academy offering mentoring, networking, and skill-building .

🧭 5. Alignment with Congressional Priorities & Program Missions

Each program is guided by yearly appropriations and congressional mandate. Success depends on tightly aligning proposals with specific program objectives and anticipated topics  .

🗓️ 6. Timely Preparation Amid Short, Dynamic RFA Windows

RFAs are brief and often come with 30–60 days lead time. Staying alert to pre-announcements, registering in eBRAP and Grants.gov, and planning early are essential  .

📊 7. Avoiding Duplication Through Informed Coordination

CDMRP actively coordinates with NIH and VA to prevent redundant funding. Before submitting, check existing programs and anticipate strategic adjustments to your proposal if overlap is flagged .

📈 Summary—What You Need to Do

Core Factor	Why It Matters
Bold, high‑impact science	CDMRP rewards innovation and high risk
Team/consortia readiness	Mechanisms favor multi‑PI, multi-institution studies
Consumer inclusion	Proposals must speak to patient relevance and include advocates
Mentoring and training plan	Especially for early- and mid-career awards
Strict alignment with program scope	Tailor aims to each RFA and congressional intent
Rapid response capability	Be ready to mobilize within 1–2 months
Portfolio awareness & distinctiveness	Show how your proposal complements—not duplicates—other programs

💡 Winning Tips

Track pre-announcements—sign up for CDMRP alerts and maintain your eBRAP profile.

Review recent funded summaries—understand what CDMRP programs value and shape your proposal accordingly.

Plan and build consortia early—ensure collaborators are involved from concept development to submission.

Engage consumer advocates—integrate patient or stakeholder perspectives in your aims and review process.

Check overlap and coordinate—avoid redundancy with NIH/VA programs; emphasize unique CDMRP-relevant aspects.

Prepare for fast turnarounds—have draft aims, compliant budgets, and institutional approvals ready to go.

Leverage nested training/career awards—if eligible, use them to build capacity and complement your full proposal.

🔧 Final Thought

CDMRP funding favors bold, multidisciplinary teams tackling high-priority challenges with consumer engagement, aligned to congressional mandates, and ready for rapid deployment. Proposals that demonstrate these qualities—and address career development—are strongly positioned to win.

Specialties

Cancer

Oncology

Eligibility Requirements

Organization Extramural and intramural organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.

Extramural Organization: An eligible non-Department of Defense (DOD) organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD (i.e., intragovernmental organizations), and research institutes.

Intramural DOD Organization: Refers specifically to DOD organizations including DOD laboratories, DOD military treatment facilities, and/or DOD activities embedded within a civilian medical center.

Principal Investigator

Independent investigators with a faculty-level appointment (or equivalent) may be named as a Principal Investigator (PI). Individuals affiliated with an eligible organization are eligible to be named as PI regardless of ethnicity, nationality, or citizenship status.

Sponsor Details

Sponsor Institute/Organizations: Congressionally Directed Medical Research Programs

Sponsor Type: Corporate/Non-Profit

Address: 1077 Patchel Street Fort Detrick, MD 21702-5024 Phone: (301) 619-7071

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity